Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes

• Ambalavanan, Jayachidambaram ^[1] ; Bhasin, Kanchan ^[2] ; Shah, Viral N. ^[2]
  1. [1] Division of Endocrinology, Diabetes and Metabolism, Maine Health Maine Medical Center and Tufts University School of Medicine, Scarborough, ME, USA
  2. [2] Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN, USA
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 55, Nº. 3, 2026, págs. 537-546
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • SGLTi can serve as useful adjuncts to insulin therapy in patients with type 1 diabetes, particularly those with heart failure, chronic kidney disease, or elevated atherosclerotic cardiovascular disease risk. Careful patient selection, counseling on risks and benefits, and initiation at the lowest effective dose can minimize complications, while insulin reductions should generally not exceed 20% to prevent euDKA. Patient education on ketone monitoring and DKA prevention as highlighted by the